Absorption, distribution, metabolism, excretion, and pharmacokinetics of remibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, in healthy participants at steady state.
- DOI
- 10.1016/j.dmd.2026.100417
- Published
- 2026 Oct 8
- Container
- Drug metabolism and disposition: the biological fate of chemicals
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.dmd.2026.100417,
title = {Absorption, distribution, metabolism, excretion, and pharmacokinetics of remibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, in healthy participants at steady state.},
author = {James AD and Lozac'h F and Hackling M and Lozac'h MA and Shah B and Hardy J and Drollmann A and Roffel A and Lefèvre G},
year = {2026},
journal = {Drug metabolism and disposition: the biological fate of chemicals},
doi = {10.1016/j.dmd.2026.100417},
url = {https://doi.org/10.1016/j.dmd.2026.100417}
}RIS
TY - JOUR TI - Absorption, distribution, metabolism, excretion, and pharmacokinetics of remibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, in healthy participants at steady state. AU - James AD AU - Lozac'h F AU - Hackling M AU - Lozac'h MA AU - Shah B AU - Hardy J AU - Drollmann A AU - Roffel A AU - Lefèvre G PY - 2026 JO - Drug metabolism and disposition: the biological fate of chemicals DO - 10.1016/j.dmd.2026.100417 UR - https://doi.org/10.1016/j.dmd.2026.100417 ER -
APA
AD, J., F, L., M, H., MA, L., B, S., J, H., A, D., A, R., & G, L. (2026). Absorption, distribution, metabolism, excretion, and pharmacokinetics of remibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, in healthy participants at steady state.. Drug metabolism and disposition: the biological fate of chemicals. https://doi.org/10.1016/j.dmd.2026.100417
Source records
- pubmed · retrieved 2026-11-10T11:28:05.964Z